3 questions about switching.
Do not use a universal conversion or washout chart. Semaglutide and tirzepatide products have different labels and titration. The prescriber should set timing and starting dose from the exact products, indication, tolerance and clinical history.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
“Pen to vial” is not a dose conversion. Verify the exact drug, formulation, concentration, container, prescription, syringe scale and instructions with the pharmacist. Compounded products are not automatically identical to an approved brand.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
Container type alone does not determine quality, price, approval or dosing simplicity. Compare the exact product, concentration, sterility controls, labeling, pharmacy status and Instructions for Use.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
← All FAQ topics | Browse all peptides
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify